A novel synthetic haemabsorption column (Cytosorb TM ) has recently become commercially available. We describe its use in patients with overwhelming sepsis and consider the experience and evidence supporting its use. While Cytosorb haemabsorption is mechanistically distinct from other extracorporeal therapies in sepsis and appears effective in reducing inflammatory cytokines during sepsis, much of the basic science and clinical benefits remain unclear. Significant interactions including removal of antibiotics may be harmful and require further study. Suggestions for future research and how Cytosorb TM could be incorporated into practice are provided.

Note from editor ConsentThis article has been accepted for publication as a letter rather than a case report due to an inability to contact the patient to gain written or verbal consent for publication. The letter has been anonymised, and the author affiliations are available by request to the Editor-in-Chief. The manuscript has undergone extensive review by JICS editors and the Editor-in-Chief of another medical journal in order to ensure that the principles behind its publication strictly adhere to the guidance of the Committee on Publication Ethics. Caldicott Guardian approval for its publication has been given by the Executive Medical Director of the Trust in which the patient was treated. All reviewers believe that the message being imparted justifies its publication albeit in an anonymised form.